Skip to main content

Advertisement

Table 2 Potential risk factors associated with eradication failure

From: Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?

  Group A (n = 100) Standard Sequential Therapy Group B (n = 100) Levofloxacin-based Sequential
  Success (n = 90) Failure (n = 10) p/OR (95%CI) Success (n = 79) Failure (n = 21) p/OR (95%CI)
Age 52.1 ± 1.8 55,5 ± 3,8 0.528 55.7 ± 1.6 47.7 ± 3.9 0.068
>65 years 23 (25.6%) 2 (20%) 0.720 23 (29.1%) 7 (33.3%) 0.708
Female 50 (55.6%) 5 (50%) 0.738 49 (62%) 11 (52.4%) 0.423
Smoking habits 6 (6.7%) 2 (20%) 0.182 5 (6.3%) 3 (14.3%) 0.359
Alcohol consumption 16 (17.8%) 3 (30%) 0.350 8 (10.1%) 2 (9.5%) 0.952
Non-ulcer dyspepsia 14 (17.9%) 0 0.353 63 (83.3%) 20 (95.2%) 0.112
Metronidazole (vs. Tinidazole) 38 (42.2%) 9 (90%) 0.006/10.15 (1.34–77.15) 16 (20.3%) 3 (14.3%) 0.756
Metronidazole 1000 mg (vs. 1500 mg) 7 (7.8%) 7 (70%) 0.001/ 8.25 (1.95–34.89) 4 (25%) 0 0.964
1st Generation PPI (vs. 2nd Generation) 74 (82.2%) 7 (70%) 0.396 69 (87.3%) 20 (95.2%) 0.450
Half-dose PPI (vs. full-dose) 4 (4.4%) 5 (50%) 0.001/ 10.11 (3.60–28.41) 5 (6.3%) 7 (33.3%) 0.001/3.67 (1.86–7.22)
Prescription by non-Gastroenterologist 20 (22.2%) 1 (10%) 0.684 2 (2.5%) 4 (19%) 0.017/3.68 (1.81–7.50)
  1. CI95% 95% confidence interval, OR odds ratio, PPI proton-pump inhibitor